Benitec Selects University of California, San Diego, as a Site for Phase I/II Clinical Trial of TT‐034
Cinnamon Girl said
Apr 17, 2013
Benitec Selects University of California, San Diego, as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
SYDNEY, April 15, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego (UCSD), Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections (HCV). Benitec previously announced the selection of Duke Clinical Research Unit as the other site.
TT-034 is being developed as a potential "one-shot-cure" for HCV.
Benitec Selects University of California, San Diego, as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
SYDNEY, April 15, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego (UCSD), Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections (HCV). Benitec previously announced the selection of Duke Clinical Research Unit as the other site.
TT-034 is being developed as a potential "one-shot-cure" for HCV.
Link to article...
http://hcvadvocate.blogspot.ca/2013/04/benitec-selects-university-of.html